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Abstract: Although Alzheimer’s disease (AD) was first discovered a century ago, we are still facing a lack of definitive 
diagnosis during the patient’s lifetime and are unable to prescribe a curative treatment. However, the past 10 years have 
seen a “revamping” of the main hypothesis about AD pathogenesis and the hope to foresee possible treatment. AD is no 
longer considered an irreversible disease. A major refinement of the classic -amyloid cascade describing amyloid fibrils 
as neurotoxins has been made to integrate the key scientific evidences demonstrating that the first pathological event oc-
curring in AD early stages affects synaptic function and maintenance. A concept fully compatible with synapse loss being 
the best pathological correlate of AD rather than other described neuropathological hallmarks (amyloid plaques, neurofi-
brillary tangles or neuronal death). The notion that synaptic alterations might be reverted, thus offering a potential curabil-
ity, was confirmed by immunotherapy experiments targeting -amyloid protein in transgenic AD mice in which cognitive 
functions were improved despite no reduction in the amyloid plaques burden. The updated amyloid cascade now inte-
grates the synapse failure triggered by soluble A-oligomers. Still no consensus has been reached on the most toxic A 
conformations, neither on their site of production nor on their extra- versus intra-cellular actions. Evidence shows that 
soluble  oligomers or ADDLs bind selectively to neurons at their synaptic loci, and trigger major changes in synapse 
composition and morphology, which ultimately leads to dendritic spine loss. However, the exact mechanism is not yet 
fully understood but is suspected to involve some membrane receptor(s). 
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INTRODUCTION 
Alzheimer’s disease (AD) is the most common form of 
dementia in the elderly with half of all individuals over 85 
years old developing it. AD is affecting over 4.5 million in-
dividuals in the United States and roughly more than 25 mil-
lion individuals worldwide [1]. Even more individuals suffer 
from mild cognitive impairment (MCI), a disorder associated 
to memory loss thought to represent a transitional step be-
tween normal memory function and dementia [2,3]. AD, 
especially in its early stages, is a pathology of memory. This 
neurodegenerative disorder is characterized predominantly 
by initial alterations in recent memory, followed by progres-
sive memory deficits, personality changes, and ultimately a 
complete loss of intellectual ability [2,4]. It is therefore not 
surprising that a large number of scientists have been trying 
to define AD etiology and to search for the devilish sub-
stances that are robbing people of their memories in the hope 
to develop treatments, which would prevent and combat de-
struction of cognitive functions and AD progression. Genetic 
and epidemiologic studies have established that early-onset 
AD is associated to dominantly inheritable mutations in at 
least one of three genes {APP, Presenilin-1 (PS1) and Prese-
nilin-2 (PS2), see reviews [5,6] and references therein}. 
These mutations lead to increased production of amyloid  
peptide (). Development of sporadic late-onset AD is as-
sociated to age, vascular factors, inflammation and diabetes 
as well as established susceptibility genes such as apolipo-
protein E (APOE) [7-10] and the most recently discovered  
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SORL1 [11]. These genes have been shown to increase  
deposition. Other genetic association studies in non-mende- 
lian AD have proposed polymorphisms in various genes such 
as LRP1, MAPT, BDNF, IDE, A2M and ACE [8,12]. While 
the scientific community came to a universal acceptance 
about the role of the above-mentioned genes in AD, the basis 
for the early memory specificity of AD has not yet been 
completely revealed. 
Hundred years ago, Dr. A. Alzheimer provided us with 
the first anatomical description of major brain neuropa-
thological hallmarks found in the brain of a 55-year-old fe-
male patient, which he followed clinically for over 4 years 
before her death. His patient initially presented rapidly pro-
gressive impairment of memory associated to total helpless-
ness and profound disorientation which evolved to general 
dementia. In her postmortem brain, Dr Alzheimer reported 
brain atrophy, presence of extracellular neuritic plaques, 
neurofibrillary tangles (NFTs) and massive neuronal loss 
(reviewed in [13]). Neuritic plaque and NFTs are the charac-
teristic neuropathological signs that are still the main prereq-
uisites the anatomopathologist uses during postmortem 
analysis to establish the diagnosis of AD according to vari-
ous widely accepted criteria [14,15]. 
Other neuropathological hallmarks of AD include syn-
apse loss, cholinergic and glutamatergic neuronal loss, glio-
sis and brain atrophy [16-19]. However, NFTs and amyloid 
deposits are constantly observed throughout the brain of eld-
erly and centenarian individuals that had not previously met 
clinical criteria of dementia [20-23]. These lesions may be 
present for years without appreciable synaptic damage or 
neuronal loss [24] presumably this correlates with the ab-
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whether these lesions represent an indication of a preclinical 
stage of AD. In non-demented cases, NFTs are usually re-
stricted to the hippocampal formation, whereas their pres-
ence in association areas of the temporal neocortex matches 
the development of obvious clinical signs of dementia [15]. 
Conversely, neuritic plaques can be abundantly found in 
several neocortical areas in MCI patients and are poor pre-
dictors of AD severity as no correlation can be established 
between their density and spatial location (e.g., in limbic and 
cortical associative areas) with the degree of the disease [25].  
We are still facing during the lifetime of the patients an 
uncertainty toward the clinical diagnosis of AD, which is 
based on standard diagnostic criteria established during in-
terviews of the patient and family relatives, physical exami-
nation, cognitive function assessments and neuron-imaging 
tests. Most of the time, the neuroclinicians will properly di-
agnose (90% accuracy) the patient with “probable” AD when 
he is truly affected by moderate or severe AD [26]. How-
ever, MCI and mild dementia often are not detected. The 
lack of sensitivity in detection has stimulated research aim-
ing at identifying AD biomarkers that will optimistically 
enter the clinical battery of tests available for the patients at 
an early time point in the disease progression. This would 
prove to be helpful for the physician to prescribe the current 
available treatment options that afford better delay in disease 
progression and therefore symptomatic benefits when admin-
istered early in the disease, ideally years before the dementia 
is diagnosed [27,28]. This review presents the remarkable 
progress that has been made in the understanding of the 
pathogenesis of AD, progress that was highly dependent on 
the development of new technologies in protein biochemis-
try, cellular and molecular biology, genetics and brain imag-
ing.  
This review will first describe: (1) facts that offered a 
“face-lift” to the main amyloid cascade hypothesis that now 
emphasizes the alteration of synaptic function and mainte-
nance as an early stage of the disease, (2) evidence that 
pointed out to synapse dysfunction and loss in clinical stud-
ies and transgenic mice models of AD, (3) supporting data 
showing that soluble A oligomers or ADDLs are the main 
neurotoxins which target particular synapses and (4) indica-
tions on how, possibly acting through putative receptors, 
downstream mechanisms might be used by soluble A to 
trigger changes in spine composition and morphology.  
THE CLASSIC AMYLOID CASCADE HYPOTHESIS 
REVISITED  
The amyloid plaques and tangles, described by Alz-
heimer, are composed of insoluble extracellular deposits of 
fibrillar A peptide and intraneuronal hyperphosphorylated 
tau aggregates respectively [29-32]. AD is now considered a 
prime example of protein misfolding disease [33]. For years, 
researchers have tried to determine if these neuropathologi-
cal hallmarks are the cause of cognitive dysfunction ob-
served in AD or if they just represented consequences of the 
real AD contributing causes. The prevailing constituent of 
the amyloid plaques, the fibrillar A, was largely studied 
[34,35] and appears to decrease neuronal viability in rat pri-
mary hippocampal culture and to activate microglial cells 
[36,37]. At the time, Lorenzo and Yankner believed that pre-
venting the fibrillation of  rendered the molecules harm-
less [38].  
There is an uninterrupted debate as to the relative impor-
tance of /plaques and tau/tangles to AD process. Initial 
studies by Yankner’s and Klein’s groups trying to establish a 
potential connection and causality between the two main 
hallmarks proposed that fibrillar  induced the phosphory-
lation of tau in vitro [39,40]. In fact,  deposition precedes 
the appearance of neurofibrillar tangles in human brains [41]. 
More recently, LaFerla’s group showed that A immuno-
therapy, by reducing the amyloid plaque load lessen tau pa-
thology in their triple transgenic animal model of AD, which 
would suggest that  and amyloid plaques are responsible 
for tau pathology [42].  
A, as a monomeric form, is a naturally occurring highly 
hydrophobic peptide [43] that is generated via cleavage of 
the transmembrane glycoprotein APP (amyloid precursor 
protein) by 2 consecutive aspartyl proteases (see reviews 
[44-46] and references therein). Briefly the cleavage by -
site APP-cleaving enzyme (BACE) at the N-terminus of APP 
is the initiating step for amyloidogenesis. Subsequently, the 
-secretase membrane complex containing presenilin (PS) 
amongst 3 other proteins cleaves APP in its transmembrane 
domain resulting in the extracellular release of the A [47]. 
Although some of the  can be generated in the endosomal 
vesicles or intermediate compartments and remained in the 
cell creating a pool of intracellular A [48-50] that can also 
be released presynaptically. Released A peptide afterward 
self-associates into either fibrils accumulating in amyloid 
plaques or oligomers, which are diffusible and soluble spe-
cies [51-56]. PS-1 has loose substrate specificity. It does not 
only cleave other transmembrane proteins such as Notch and 
ErbB4, but it also cleaves APP at different positions result-
ing in the formation of several variants of  which differ by 
the length of their carboxyl terminal (from 38 to 42 amino 
acids) [57,58]. The most common form of A is A1-40, a 40 
amino acids in length, which is normally secreted from cells 
and is suspected to be physiologically active [59]. The A 
peptide 42 amino acids long (A1-42) presents a more hydro-
phobic C-terminal, which provides a greater propensity to 
aggregate [60]. Its production is highly increased in AD pa-
tients where a shift in favor of the 42 instead of 40 is 
readily observable. Still, it is debated if there is a commonal-
ity or independence in the pathway leading  to the aggre-
gation into oligomers and fibrils [61,62]. It is particularly 
interesting here to remember that one of the first description 
of the core of amyloid plaques from AD and Down syn-
drome (DS) showed that it was composed of multimeric ag-
gregates of A (mainly dimers, trimers and tetramers) that 
are soluble in formic acid and identifiable by SDS-PAGE 
and HPLC. At this time, multimeric assemblies were be-
lieved to be part of the ongoing A fibrillogenesis [63].  
Integrating years of research on the deleterious effects of 
, Hardy and Higgins proposed in the 90’s the original 
“amyloid cascade hypothesis” [64]. This hypothesis de-
scribed key steps that once dominated the train of scientific 
thinking for all research in the field of AD. They hypothe-
sized that neurodegeneration occurring in AD is attributable 
to the accumulation of insoluble fibrillar  species into 
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neurofibrillary tangles subsequently followed by a massive 
neuronal loss leading to the observed dementia [64]. Some 
studies also suggest that A disrupts calcium homeostasis 
[65], causes free radical generation [66] and various forms of 
peroxidative injury [67,68], and activates glia and microglia 
[69]. The dreadful role of  was subsequently reaffirmed 
through a better understanding of the APP cleavage pathway 
and the genetic studies of APP and PS1 missense mutations 
(reviewed in [70-72]).  
Afterward, other supports for this hypothesis were pro-
vided by the generation, in various laboratories, of transgenic 
AD mouse models (AD-Tg) carrying mutated genes or 
knock-in or knock-out genes that are involved in some famil-
ial forms of AD [73-76]. The most commonly used are the 
PDAPP, Tg2576, APPswe, APP/PS1 and 3xTg. These ge-
netically modified mice develop progressive AD-type pa-
thologies such as age-related elevated levels of A and amy-
loid plaque deposition in the hippocampus and neocortex, 
tau hyperphosphorylation and variable synapse loss. For 
comprehension of their relevance to AD research, further 
details on the neuropathological characteristics of all created 
transgenic AD models can be found in the following reviews 
(for recent reviews [76-80]). AD-Tg mice also present age-
dependent cognitive impairment in various learning and 
memory tasks [81-85]. Yet, these mice often do not present 
some of the other major neuropathological hallmarks of AD 
such as massive neurodegeneration or neurofibrillary tangles 
(NFTs) [77]. Neuronal loss, mostly in the hippocampus, was 
more frequently observed in the multiple transgenic mice 
[86-88]. Hitherto, these observations strengthened the hy-
pothesis that AD neuropathology was resulting from the ag-
gregation of A and directly correlated  aggregates with 
memory impairments.  
It soon became evident that the original amyloid cascade 
hypothesis was not suitable to explain entirely the cellular 
and molecular mechanisms triggering the full range of neu-
ropathologies associated with AD. The principal disap-
pointment stems from the inconsistency between the amyloid 
plaque load in AD brains and the degree of AD dementia, an 
imperative correlation for a hypothesis asserting that mem-
ory loss is a direct result of fibrillar A [89,90]. Although 
some reports showed significant correlations of plaque num-
ber with dementia [91,92], numerous studies have found 
only weak or no correlation between neocortical plaque den-
sities and clinical severity measures [90,93-95]. A better 
correlation with cognitive impairment status shows up when 
the total A burden is detected with A specific antibodies 
[96]. Instead, densitometric measurement of synaptic popula-
tion correlated much better with the cognitive performances 
of the AD patients [90,97]. Another group even proposed 
that distribution and abundance of NFTs are greatly associ-
ated with the clinical progression of AD [15].  
The original amyloid cascade hypothesis also claimed 
that fibrillar A ultimately killed neurons, suggesting an 
irreversibility of the disease. However, as mentioned above, 
the AD-Tg rarely present neuronal loss. In addition, surpris-
ing evidence obtained from a vaccination study in an AD-Tg 
refuted the irreversibility. Paul’s group passively immunized 
with a monoclonal antibody against A some APP-Tg mice 
that have developed numerous amyloid plaques and pre-
sented memory impairments. Shortly after the vaccination, 
the mice showed a recovery of memory impairment despite 
the lack of reduction in the amyloid plaque load [98]. These 
results were supported in independent studies using a differ-
ent monoclonal A antibody and a different APP-Tg mice 
[99]. A major stumbling block to the amyloid hypothesis has 
arisen following these studies bringing contradictions to the 
initial thinking. The prompt reversal of memory loss ob-
served in the vaccinated
 mice occurring despite no decrease 
in plaque load was totally inconsistent
 with a mechanism for 
memory loss dependent on neuronal death caused
 by amyloid 
fibrils. Researchers were faced with the following questions: 
How can memory loss be reversed if it is attributable to neu-
ron death? In addition, how can memory recovery occur in-
dependently of A plaque levels if memory loss is resulting 
from fibrillar  species? Studies demonstrated that block-
age of fibrillar  formation by the protein clusterin also 
called ApoJ, which is highly expressed in amyloid plaques, 
did not prevent  toxicity but to the contrary enhanced it 
[100]. A reevaluation of the amyloid cascade took into ac-
count the idea that memory failure derives from neuronal 
dysfunction rather than degeneration. AD has therefore 
ceased to be considered as an inescapable consequence of 
irreversible ageing. 
New investigations were aimed at identifying the agent 
responsible for this fibril-free toxicity. Klein’s group charac-
terized alternative A assemblies and reported the presence 
of pathologically hidden neurotoxic assemblies of diffusible 
synthetic A oligomers in the presence of clusterin [101], 
assemblies that can also occur in the absence of clusterin 
[102-105]. Non-fibrillar  assemblies can be found in hu-
man brains of AD and Down syndrome (DS) patients prior to 
amyloid plaque formation [106,107] and are secreted natu-
rally by cultured cells [108]. Concurrently, studies done in 
human brain demonstrated the presence of soluble A con-
centrations which were highly correlated with disease sever-
ity [109,110], a correlation that has been confirmed with 
studies of MCI patients [111].  
In 2002, Hardy and Selkoe proposed a revised amyloid 
cascade hypothesis incorporating as central role players the 
small soluble  oligomers which are formed prior to fibril-
lar  deposits. These oligomers are strongly believed to be 
the “memory-thieves” as they are particularly eager to im-
pact synapse signaling, shape and stability before neuronal 
death occurs (description below). Indeed, many investigators 
have suggested that these oligomers constitute the main 
causative agent by interfering with neuroplasticity in the 
pathogenesis of AD [12,19,101,103,112,113-115]. This hy-
pothesis really came forward after the demonstration that A 
oligomers, which rapidly and selectively inhibit long-term 
potentiation (LTP), a classic experimental paradigm for 
memory and synaptic plasticity, did not seem to affect basal 
synaptic transmission, suggesting that the synaptic alteration 
observed was initially non-degenerative [56,101,116-119]. 
Recent findings have validated the revised hypothesis by 
demonstrating that soluble  oligomers have clinical rele-
vance. In fact, oligomers are strikingly elevated in AD-Tg 
[120] and, most significantly,
  in AD brain [121-123]. The 
updated amyloid cascade has already provided the founda-
tion for pharmaceutical programs intending to develop drugs 
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[124] but it should also be noted that some of the events 
downstream of  accumulation are still unsolved. It might 
also not be perfectly safe to develop therapeutics interfering 
with  clearance that could affect dissociation of fibrillar 
 into potentially synaptotoxic  oligomers. Therapies 
that would eliminate  pathology might prove to be insuf-
ficient if given at advanced disease stages [125]. In fact, re-
cent clinical trials using vaccine against  in AD patients 
have effectively decreased amyloid plaques burden, but not 
NFTs, and have conferred moderate clinical benefits [126-
129]. Can the revised amyloid cascade survive without fur-
ther re-examination? The basis for an “indirect amyloid hy-
pothesis” has recently come to light. In this new hypothesis, 
leaders in the pharmaceutical industry have pointed out the 
need for further research that will not exclusively revolve 
around the generation and accumulation of A but take into 
account parallel events and therefore provide alternative tar-
gets (e.g., tau protein and apolipoprotein E) [130].  Addi-
tional basic research studies need to be conducted to help the 
development of treatment that will afford cognitive im-
provements to AD patients and ultimately will stop -
dependent pathologies such as tau accumulation, oxidative 
stress and neurodegeneration. These treatments would ide-
ally provide help to patients at whatever stages of the diag-
nosis they are found in while progress is made in the devel-
opment of reliable brain imaging techniques and early detec-
tion of AD markers such as some of the recent nanotechnol-
ogy based assay developed to measure soluble  in the 
CSF [131]. 
SYNAPSE PATHOLOGY IN AD AND AD-TRANS- 
GENIC ANIMALS 
Among the series of abnormal alterations in the AD 
brain, the most significant proximal events are loss of syn-
apses (pre- and post-synaptic compartments) and neuronal 
cell death. The majority of original reports on organized neu-
ronal networks, structure-wise, were obtained using the 
Golgi impregnation of cerebral cortex samples obtained from 
deceased AD patients. Despite the known technical limita-
tions of this method, such as a non-selective and poor sam-
pling of neurons (2-10% of the neurons being labeled), it 
provided the first substantiation of dendritic damage with 
marked spine loss in AD [132]. More recently, proteomic 
and genomic studies, conducted in humans and AD-Tg, have 
confirmed the downregulation of genes involved in synaptic 
maintenance and function (e.g., signal transduction, synaptic 
vesicle machinery, exo- and endocytosis related genes, cal-
cium binding and cytoskeleton) convoyed by overexpression 
of cellular stress response molecules early in the disease 
progression [133-141]. Beside the fact that  can impact 
the expression of synaptic proteins and regulate synaptic 
mechanisms involved in memory processing, it is also possi-
ble that synaptic dysfunction in AD results, at least in part, 
from inherited variations in synaptic genes.  
Dendritic spines are the post-synaptic compartment of the 
synapses and are virtually where all excitatory afferences 
make contacts on hippocampal and cortical pyramidal cells 
in adult brain [142]. Dendritic spines therefore reliably re-
flect the number of synapses and are often used as an index 
for synaptogenesis and synaptosis [143]. They also represent 
sites where significant changes are made to accompany func-
tional and structural plasticity [144,145]. 
Dramatic loss of synapses and dendritic spines in AD 
was confirmed by morphometric analysis both in autopsied 
and biopsied AD samples. More than 50% spine loss was 
observable in hippocampus and neocortex [146,147] and 
synapse loss was noticeable on surviving neurons as well 
[97]. 
Development of specific antibodies for synaptic markers 
has provided new tools to assess the synapse loss in AD. 
Levels of synaptophysin (a protein highly expressed in pre-
synaptic terminals) quantified within key memory centers of 
the brain (e.g., frontal cortex and hippocampus) were highly 
decreased and strongly correlated with the degree of memory 
impairment assessed by cognitive tests before the AD pa-
tient’s death [90,148-150]. Synapse loss was not restricted to 
areas surrounding plaque deposition [151].  
In AD-Tg, no correlation was found either between 
plaque load and synapse loss but synapse loss correlated well 
with increased levels of soluble  [86,152-154] particularly 
in regions highly involved with memory processing such as 
the perforant path input from the entorhinal cortex to the 
dentate gyrus. Synapse loss seems to be the first morpho-
logical sign in the neuronal dysfunction and as depicted in 
the 3xTg, synapse loss and disrupted LTP appeared prior to 
plaque deposition, formation of tangles or cell death. 
Nonetheless, synapse loss seems to appear after the sur-
facing of cognitive impairment which points to the possibil-
ity that initial events rather implicate “synaptic failure” prior 
to the established “synaptic slaughter” and neuronal loss in 
AD [19,155,156].  
Recently, quantitative immunoblotting experiments aimed 
at measuring synaptophysin (SVP), synaptotagmin (STG) 
and drebrin (DRB) levels [157] in tissues samples from the 
Religious Orders Study (ROS) [158] revealed differential 
regulation of these markers in 5 neocortical regions both in 
MCI and mild/moderate or severe AD. Levels of SVP selec-
tively decreased in the superior temporal and inferior parietal 
cortex of severe AD and correlated with MMSE scores. 
However, levels of STG were unaffected. DRB, an f-actin 
binding protein localized in dendritic spine heads of excita-
tory synapses which plays a role in synaptic plasticity by 
regulating spine morphogenesis and formation of postsynap-
tic densities [159,160], was decreased depending on the in-
vestigators from 40 to 90% in cortical regions [161,162] and 
~70-80% in hippocampus of patients with severe AD [163]. 
DRB levels in the anterior cingulated, superior temporal and 
visual cortex correlated with MMSE and its decrease is ob-
servable in MCI as well [157]. A shift in drebrin represents a 
good indicator of changes in dendritic spine density. Pro-
gression of cognitive decline during the clinical course of 
AD may be related to a loss of excitatory postsynaptic con-
tacts within vulnerable brain regions. If NFT formation plays 
a role in postsynaptic marker loss remains an open question 
[134,164]. NFT deposition might be associated with de-
creased transsynaptic efficacy in some cortical region. In-
crease of DRB was found in superior frontal cortex in MCI 
subjects with Braak stage II-IV (high limbic stage), consis-
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throughout cortex of non- or mild-demented subjects with 
Braak stage IV [165]. At this stage, NFTs are relatively 
sparse in regions involved in executive functions (frontal 
cortex) but are abundant in regions involved in associative 
behaviors such as memory and language (temporal cortex) 
[15]. Therefore, increase in postsynaptic markers in specific 
brain regions may represent a dendritic structural reorganiza-
tion to preserve cortical neurotransmission despite the 
mounting neuropathological damage. Significantly, there is 
an upregulation of ChAT activity in the same brain regions 
in MCI from the ROS cohort [166].  
Studies above demonstrate that initial plasticity responses 
in some brain regions contribute to functional preservation at 
least during early stage of AD. A model for synapse mor-
phology alterations during AD progression was actually pro-
posed by Scheff and Price [167]. AD synapse pathology be-
gins with a slight loss of synapses resulting from cholinergic 
and glutamatergic deafferentation [168,169], which is then 
accompanied by a decrease in the number of dendritic spines. 
Over time, new synaptic contacts are formed by sprouting 
from adjacent afferent terminals, which occurs concurrently 
with the enlargement of pre-existing synapses in the attempt 
to compensate for early synapse loss. However, the compen-
satory mechanisms are eventually overwhelmed as the dis-
ease progresses, resulting in a net decrease in synaptic con-
tact area [167]. The loss of synaptic contact area interrupts 
functional neural circuits, resulting in cognitive deficits 
[170]. Further evidences of -associated synaptic pathol-
ogy come from studies of patients with DS and AD-Tg.  
DS patients present cognitive deficits and early onset AD 
[171]. In these patients, overexpression of APP resulting 
from an extra copy of chromosome 21 induces increase in 
amyloid levels associated to a decrease in spine density. The 
“surviving” spines are morphologically different, rather 
larger or thinner, than spines expressed in non-demented 
subjects [147,172,173]. Decreased levels of dendritic spine 
marker proteins such as synaptosomal associated protein 27 
[174] and F-actin bundling proteins (such as drebrin and 
moesin) [161,175,176] in DS patients also suggest synaptic 
defects consistent with the memory deficits seen in patients, 
and with abnormalities in synaptic plasticity such as LTP 
seen in DS-Tg model mice [177,178]. 
Conflicting information on synaptic pathology have been 
gathered throughout the years in various engineered AD-Tg 
models, [179] but most of the lines present some degree of 
changes in synaptic marker expression [180-184]. More re-
cently, using the latest in vivo imaging techniques (i.e, DiO-
listic method coupled to intravital multiphoton microscopy 
and high throughput morphometric analysis or PET & MRI), 
marked dendritic spines loss was reported in specific brain 
regions [185-189]. Shelansky’s group first showed using 
fluorescent dyes that the postsynaptic sites of the synapses, 
the dendritic spines, were dystrophic and less dense in AD 
models than age-matched control samples and, in support of 
neurotoxicity induced by soluble  species, these deficits 
were not confined to plaque deposited regions [186]. Inter-
estingly, dendrites traveling through plaques can still harbor 
spines but their morphology is different from that of the 
amyloid-stained dystrophic neurites surrounding them. In 
AD-Tg, loss of synaptic terminals and pre- and post-synaptic 
markers is rather convincing [88,181,190] and is also consis-
tent with decreases in transcripts of multiple synaptic genes 
[137,155]. In Ts65Dn, a mouse model of DS with severe 
amyloid deposition, dendritic abnormalities are characterized 
by less spinous and less branched basal dendrites of frontal 
cortex pyramidal cells compared to diploid controls [191].  
However, there is still a lack of consensus on the rela-
tionship between plaque load and synapse loss in AD-Tg. 
Some investigators proposed that synapse loss occurs to cer-
tain degree independently from extracellular amyloid deposi-
tion (happening prior to or at distance from it) and correlates 
well with increasing levels of soluble  [152,154,185, 
188,192,193]. Other groups reported, using in vivo meas-
urement, a higher decrease in dendritic spine density in or 
nearby amyloid plaques, emphasizing that fibrillar amyloid 
deposition leads to local synaptic abnormalities and breakage 
of neuronal branches [187,194-196].  
This appears to be in contradiction with the “soluble  
oligomer hypothesis” but it should be considered that 
plaques might possibly be a reservoir for toxic soluble oli-
gomeric forms of b [53]. It should also be noted that, solu-
ble forms of  have not yet been made readily observable 
for in situ microscopy particularly because of their diffusible 
nature and the lack of dye/reagents usable for imaging. 
While they are cryptic to the neuropathologist, their levels 
can be estimated by biochemical techniques.  
Novel technical developments, combining high resolu-
tion imaging techniques and the manufacture of high affinity 
amyloid-binding compounds (e.g., “Pittsburgh Compound 
B”), will certainly enable us soon to determine better the 
spatial resolution of the amyloid plaques (neuritic or diffuse) 
in living subjects. It is now possible to detect cerebral amy-
loid deposits by in vivo PET detection [197-199] and such 
approaches have been successful not only in the AD-Tg 
models but also in living human subjects giving hope for 
future diagnostic tools in AD field [200].  
SOLUBLE A-OLIGOMERS AS IDENTIFIED GAIN-
OF-FUNCTION SYNAPTOTOXINS 
After many years of research on amyloid toxicity, it has 
become evident that, even if the harmless monomers of  
require to self-associate in order to become neurotoxic, the 
ultimate aggregational state (fibrils) might not be carrying all 
or even any of the neurotoxic effects [12,113,201,202]. This 
section will review evidences in favor of the soluble -
induced synaptic failure. 
1-42 monomer, a peptide with a better propensity for 
aggregation than 1-40, can adopt different multimeric 
assemblies communally termed “soluble ” with differ-
ently conformed soluble  aggregates exhibiting most 
likely a large spectrum of toxicity and playing a fundamental 
role in AD pathogenesis [56,203]. Some reports in the litera-
ture describe better than others the type of  species stud-
ied while other apply freshly dissolved 1-40/42 without a 
clear definition of the assembled status reached in their ex-
perimental conditions. Comparison between studies therefore 
need to consider this carefully because the aggregated forms 
attained depend on the concentration of  and experimental 
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1-40 or 1-42 [204]. In fact, it has become evident that 
1-40 and 1-42 use different oligomerization and fibril-
lation pathways and while 1-42 creates multiples  as-
semblies from 3-mers to protofibrils, 1-40 mostly appears 
as 1-4mers prior to become fibrils [61,62]. The term “soluble 
oligomer” has a more general use as it takes in all soluble 
forms of  just after its production by the cells or the solu-
ble aqueous fractions obtained either from brain extracts or 
from the synthetic  peptide preparations. 
Investigating the role of soluble oligomers in the patho-
genesis of AD presents difficulties mostly in distinguishing 
these soluble metastable assemblies from mature fibrils and 
soluble monomers. Detection methods comprise mainly SDS 
gel electrophoresis, gel filtration, circular dichroism, light 
scattering, size exclusion chromatography (SEC), atomic 
force microscopy (AFM) and electron microscopy. Further 
characterization was recently facilitated by using the PICUP 
method which “stabilizes” the oligomeric species in their 
adopted molecular organization [205]. Recent immuno- and 
nanotechnology-based assays are taking advantage of the 
latest development of antibodies raised against particular  
conformations by Klein’s lab (M94, M71, M69, NUs) and 
Glabe’s lab (A11), [123,102,206]. The aggregation of  
generates a range of toxic intermediary oligomeric assem-
blies (see reviews [56,207]) for instance small/low-n oligo- 
mers (dimers, trimers; [53,108], globular oligomers/ ADDLs 
(-Derived Diffusible Ligands – 3/4-24mers; [101-105, 
208], Globulomers (38/48kDa;[209]),  oligomers/Os 
(15-20mers; [206,210]), *56 (dodecamers; [211]), ADDL-
like spherical assemblies [212,213], annular assemblies 
(Doughnut-like structures) [214] and protofibrils/high-n oli-
gomers (string of oligomers, [51,61,201,215]). It is still de-
bated if any of these intermediary forms are on the pathway 
to fibrils [54,55,61,201,202,216-218]. Further studies will 
provide possible distinction between these oligomeric as-
semblies concerning their biological activities and their neu-
rotoxic properties. In view of so many different conforma-
tions, it is legitimate to expect that different pathways might 
be activated through potential binding to membrane recep-
tor(s) or by a direct damage to the neuronal membrane. 
Presence of Soluble  in Human and AD-Tg 
In the 90’s, six major studies proposed that non-fibrillar 
42 was actually the first species to deposit extracellularly 
in the cerebral cortex of AD patients [106,110,219-222]. 
Small oligomers of A were present in SDS extracts of AD-
affected blood vessels but believed to be indicators of ongo-
ing fibrillogenesis. Roher’s group isolated water-soluble  
oligomers from normal and AD brains using a centricon 
fractionation and demonstrated that soluble  levels and 
particularly the 42 form were greatly increased in AD 
patients compared to controls, but again they considered 
these species to be intermediates en route to formation of 
toxic amyloid fibrils. Younkin’s group confirmed presence 
of soluble  species in AD brains [223,224]. Not long after, 
Roher suggested that the water soluble dimeric species are 
more neurotoxic than high molecular weight fibrillar species 
of A40 [225] whereas recent studies indicated that dode-
camers from A42 are more potent neurotoxins [114,115, 
122,202,211,226]. 
Few findings have validated the revised amyloid hy-
pothesis by demonstrating that soluble  oligomers have 
clinical relevance. Detergent-free aqueous extracts of AD 
brains have shown manifold increase of soluble forms of  
when compared to extracts of age-matched non-demented 
controls [121,122]. Most prominent species in these AD 
brain have an isoelectric point of 5.6 and a molecular weight 
around 56kDa equivalent to an assembly of 12 monomers 
[121]. Similarly, the presence of an  species, named 
*56 (for 56kDa), was found in Tg2576 mice at a young 
age, prior to amyloid plaque deposition and obvious neu-
ronal loss. In this study, trimers and hexamers were disre-
garded as potential synaptotoxic as their presence in the 
brain occurred prior to cognitive deficits. Isolated *56 
from the Tg2576 mice was subsequently injected in rats and 
triggered impairment suggesting its involvement in cognitive 
decline [211]. *56 was rather more detrimental in behav-
ioral paradigms than fibrillar  [227].  
The in situ distribution of soluble  oligomers in human 
brains was detected by either A11 from Glabe’s lab, which 
does not recognized either 2- to 4-mers or A fibrils, or 
ADDL-raised antibodies from our lab, recognizing oli-
gomers [122,123,206]. Oligomer-immunoreactive plaques 
were diffuse and did not co-distribute with Thioflavin S-
positive dense-core plaques, which contain fibrillar A. Us-
ing our oligomer-selective antibody, we described a diffuse 
immunostaining surrounding neuronal cell bodies (perineu-
ronal labeling) rather than intracellular deposits, which could 
be interpreted as apparent oligomer binding within dendritic 
arbors [122] reminiscent of the diffuse synaptic-type depos-
its observed in prion-associated diseases [228].  
Using anti-globulomer antibodies (8F5 and 5598), solu-
ble  can be found in periphery of plaques in AD and AD-
Tg as well as prior to mature amyloid plaques [209]. In AD 
brains, accumulation of soluble  was detected, using our 
oligomer-specific antibodies in an immunoblot assay, in re-
gion implicated in memory functions such as the frontal cor-
tex but not in the cerebellum which is generally preserved in 
AD [121-123]. Increased levels of soluble  was recently 
reported in biopsied temporal cortex from patients suffering 
from traumatic brain injury [229] which could explain some 
of the cognitive disturbances present in these patients [230]  
Oligomers are also strikingly elevated in various AD-Tg 
in an age-, transgene- and region-specific manner [42,120, 
211,231]. In the 3xTg mice age-dependent accumulation of 
soluble oligomers was detected using the two main oli-
gomeric antibodies available [102,123,206]. Moreover, the 
results of immunization trials referred to above strengthened 
earlier studies demonstrating significant correlations be-
tween levels of soluble  species, cognitive deficits and 
synapse loss in humans affected with AD and in various 
transgenic mouse models of AD. 
Soluble  Oligomers Obtained from Synthetic 1-42 
Preparations or from Conditioned Media of hAPP Over-
Expressing Cells  
Klein’s group has discovered the presence of pathologi-
cally hidden neurotoxic assemblies of  named ADDLs. 
They are small diffusible globular metastable assemblies   
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formed from synthetic 1-42 monomers in the presence or 
absence of clusterin [101,102,104]. ADDLs are metastable 
SDS-resistant preparations that range from trimers to 24-
mers and are temperature sensitive, with 12-mers or tetram-
ers predominating when solutions are put at 37°C or 4°C 
respectively [101,104]. ADDLs were injected into rabbits 
and mice and successfully triggered the production of 
ADDL-specific antibodies which were afterward shown to 
subdue ADDL toxicity in cell culture [102,123]. 
Simultaneously, Selkoe and Walsh groups have engi-
neered a CHO cell line, 7PA2, in which the human APP was 
inserted and they have collected several oligomeric species 
secreted from these cells. Oligomeric species contained in 
the conditioned media and separated by SEC were SDS-
stable dimers and trimers [56,108,118,232,233].  
At nanomolar concentrations, soluble A oligomers, syn-
thetically prepared or endogenously released from 7PA2 
cells caused severe impairment of long-term potentiation 
(LTP) as well as the reversal of long-term depression (LTD). 
This effect was observed after in vivo microinjection of the 
oligomers or in ex vivo experiments using hippocampal 
slices demonstrating their neurotoxic activities [19,101,113, 
116,118,234]. 
If monomers contained in the oligomeric solutions were 
eliminated by digestion with the insulin-degrading enzyme, 
inhibition of LTP was not affected, reinforcing the idea that 
oligomer assemblies are responsible for LTP blockage. It 
would indicate that the net synaptic activity is shifted toward 
inhibition and strongly suggest instability in synaptic com-
position and morphology [103,122]. Counterpart studies 
proposed that rod-like assemblies known as protofibrils 
could interfere with proper LTP [51,235]. These observa-
tions confirmed that soluble  oligomers could directly 
impair synaptic plasticity and memory formation in agree-
ment with studies demonstrating that LTP was impaired in 
some AD-Tg (e.g. PD-APP or 3xTg) before the development 
of  deposits [86,236]. Such impairment of synaptic plas-
ticity may also account for plaque-independent cognitive 
failure seen in hAPP-Tg mice [152,192,237,238], which ac-
cumulate soluble oligomers as mentioned above [120]. Solu-
ble oligomers have also been found to interfere with memory 
functions tested by widely used behavioral tests specific for 
memory assessment in rodents [211,239] and their “inactiva-
tion” by NAB61, an A oligomer-sensitive antibody, amelio-
rates memory functions [240]. The detrimental effect of oli-
gomers on LTP and impaired cognitive performance can 
therefore be annulled by specific anti- antibodies [56, 
241]. Blockage of LTP by ADDLs suggested a mechanism 
by which the neuronal dysfunction may present itself par-
ticularly in the view of their abundance in early stages both 
in AD and AD-Tg brains.  
In vitro studies, conducted in Klein’s group, showed that 
within 5 minutes both synthetic ADDLs and soluble aqueous 
extracts of human AD brain containing oligomers bind to 
hippocampal and cortical, but not cerebellar, neurons with a 
pattern that is punctate-like reminiscent of hot-spots distribu-
tion adopted by surface receptors [121,122]. In these highly 
differentiated and synapse enriched-cultures, ADDLs bind 
specifically to neurons expressing glutamatergic receptors 
but failed to bind to GABAergic neurons (GAD-positive 
cells) or to astrocytes (GFAP-positive cells) [122,226]. In-
terestingly, when added to primary hippocampal cultures, the 
CSF of AD patients, but not age-matched controls, displayed 
similar hot-spot distribution pattern of ADDL-IR punctas 
[122]. Taking advantages of a sophisticated nanotechnology 
assay, known as BioBarcode, it was demonstrated that in fact 
ADDLs accumulate in CSF of AD patients giving hope for 
the development of a biomarker for AD diagnostic [131].  
In order to advance our understanding of the mandatory 
 conformation that triggers neurotoxicity, we studied the 
punctate distribution of fractionated aqueous AD extracts 
and synthetically prepared ADDLs. Centricon filter frac-
tionation of AD extracts showed that binding activity resided 
in oligomers of molecular weights comprised between 10 
and 100 kDa, consistent with the 2D native electrophoresis 
characterization reporting dodecamers as the most prominent 
species in AD brain [121]. Similarly, when synthetic ADDL 
species were separated by centricon fractionation or HPLC 
size-exclusion chromatography, the fractions carrying the 
binding abilities were comprised between 50 and 100kDa 
consistent with the size of 12-mers and larger species, but 
not with protofibrils. No binding was obtained either from 
fractions containing monomers and small oligomers (2-,3- 
and 4-mers) [122,226]. This seems inconsistent with the syn-
aptotoxic effect afforded by the exogenously applied natu-
rally secreted oligomers (mostly dimers and trimers) 
[118,242] but in agreement with the toxicity afforded by 
larger oligomers (12-24mers) [243]. This discrepancy calls 
for further studies. One reason for this divergence that comes 
to mind is the possibility of a differential targeting location 
one being extracellular and at the synapses while the other 
might act intracellularly after endocytosis of the A species 
for example. It is also possible that both species categories 
trigger similar neurotoxic effect by different mechanisms. 
Ultimately, the difference in concentrations of the oligomeric 
species present in the two different preparations can be held 
responsible, as recently proposed by Halpain’s group [244]. 
Subsequent studies revealed that oligomeric A42 were more 
neurotoxic than monomeric and fibrillar preparations at sub-
micromolar concentrations [212]. Although 1-42 has been 
reported to accumulate intracellularly in AD and AD-Tg 
within neuritic processes and synaptic terminals [86,245, 
246], ADDL immunoreactivity on neurons was almost solely 
found at cell surfaces, even after cell permeabilization proto-
cols. 
Binding of ADDLs most probably occurs through at-
tachment to membrane protein(s) because ADDL punctas are 
lost when cells have been trypsinized [101]. Despite the fact 
that many potential membrane receptors have been proposed 
[247], the identity of the soluble  oligomers binding pro-
tein(s) is still unrevealed. Ongoing studies in search of the 
receptor(s) are building on initial ligand overlay assays, 
which monitor protein interactions, and yielded to a couple 
of membrane-associated binding partners (p140 and p260) 
from hippocampus and cortex [121].  
The distribution of ADDL punctas on dendritic arbors, as 
depicted in Fig. (1), was observed either with synthetic 
ADDLs, AD brain-derived soluble oligomers or CSF sug-
gesting that ADDLs might bind to synapses, as would be 
anticipated for a molecule that could disrupt LTP and LTD. 
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calize with PSD-95, a postsynaptic protein implicated in 
organization, function and plasticity of excitatory synapses 
[248], while 50% of all synapses are targeted by ADDLs 
[122]. Using similar quantitative analysis, Busciglio’s group 
confirmed the synaptic binding of ADDLs and Os 
(~90kDa species) on human cortical neurons [243], ADDLs 
being more synaptic than Os. In agreement with our data, 
specific binding to hippocampal neurons but not astrocytes 
was obtained with the globulomers [209]. We also confirmed 
that ADDL-binding spots are abundantly present at post-
synaptic sites. ADDLs specifically colocalize with various 
synaptic markers highly enriched in the post-synaptic sites 
such as PSD-95, CamKII, Arc, spinophilin and drebrin but 
were found apposed to the presynaptic marker synaptophysin 
[226,249,250]. Post-synaptic localization of ADDLs indi-
cated by microscopy was completed by both ELISA assay 
and subfractionation of the synaptic junctional complexes. 
By ELISA and subcellular fractionation, ADDLs were asso-
ciated with PSD rather than presynaptic active zones 
[226,251]. Further confirmations came from immunoprecipi-
tation experiments of ADDL-treated cortical synaptosomes. 
Detergent extraction of the synaptosomes yielded an ADDL-
binding complex that was in essence postsynaptic as attested 
by the presence of PSD-95 and the absence of syntaxin, a 
presynaptic active-zone protein. Further extraction by sarko-
syl and SDS detergents released PSD-95 as well as some 
fundamental subunits of the NMDA receptors. This strongly 
supports the ability of ADDLs to attack synapses where they 
can initiate local synaptic dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Upper: Neurons and more precisely dendritic spines were 
visualized on a cultured hippocampal neuron by labeling with anti-
CaMKII and anti-drebrin antibodies. Lower: immunofluorescence 
for the ADDL bound onto the hippocampal cells was revealed using 
an anti-oligomer specific antibody. Labeling reveals that ADDL 
distributed along dendritic arbors particularly attack dendritic 
spines (as demonstrated by high degree of colocalization between 
drebrin and ADDLs). 
The synaptic selectivity for a subpopulation of neurons 
needs to be further characterized. It is suspected that some 
synaptic constituents or the combination of some of them 
make some synapse particularly vulnerable. While PSD-95 is 
expressed ubiquitously in synapses throughout the brain, 
other postsynaptic constituents might be differently repre-
sented in assorted synapses. This might in turn give variabil-
ity to the subunits composition of glutamate receptors, to 
membrane receptor interactions, to the abundance of some 
scaffolding proteins (e.g., SynGAP, homer, shank, etc…) as 
well as to the abundance of molecules of the signaling cas-
cade (e.g., kinases/phosphatases and RhoGTPases). 
As mentioned above, A can be produce intracellularly 
and aggregate in a variety of subcellular compartments, in-
cluding the endoplasmic reticulum (ER), trans-Golgi net-
work and lysosomes in AD and DS patients [252]. It has 
been proposed by some investigators that intracellular accu-
mulation might be an event occurring prior to extracellular 
deposition and suggests that extracellular deposition results 
from release of intracellular  by “leaky” or “dying” neu-
rons [246]. The role of intracellular  in synapse toxicity is 
still the object of controversy. In the 3xTg and Arc mice 
(expressing the artic mutation), deficits in synaptic plasticity, 
learning, and memory appear to be associated with the 
buildup of intraneuronal A as they occur prior to plaque 
formation (see [253] for recent review). Appealing data were 
obtained from the immunization with anti-oligomer antibod-
ies which demonstrated protection against  detrimental 
effect at synapses after their internalization [254]. Clearance 
of extracellular A occurred before the clearance of intracel-
lular A in another model [255]. These studies indicate the 
importance of intracellular A [256] but raise the following 
questions: what are the respective contribution of extra- and 
intracellular  oligomers in the pathogenesis of AD? and 
what is the source of the intraneuronal A? does it originate 
from retention and subsequent aggregation of intracellularly 
generated A or does it come from the reuptake of extracel-
lular A? 
In fact, if exposure to ADDLs significantly affects synap-
tic morphology and composition which are known to influ-
ence several key aspects of synaptic transmission, it is fair to 
believe that ADDLs are the initiators of early cognitive im-
pairment observed in AD patients and participate throughout 
the progression of the cognitive impairments. Therefore, a 
“memory thief” molecule would be considered a good syn-
aptotoxin only when enough synapses of a determined mem-
ory-involved network are altered by it and both synaptic 
compensatory homeostatic mechanism and synaptic reserve 
becomes overwhelmed [257]. Remarkably, we have recently 
reported that ADDLs hold biological and physiological 
uniqueness that would be anticipated for such a synaptotoxin 
liable for AD dementia. In fact, ADDLs have been found to 
trigger changes in dendritic spine composition, density and 
structure [226,250,258,259].  
We initially showed that when ADDLs are bound at syn-
aptic sites, they can trigger some synaptic events such as the 
over-expression of Arc [122,260], a synaptic immediate-
early gene product implicated in LTP and for which the 
overexpression has been linked to dysfunctional learning 
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ADDLs also promoted a rapid decrease in membrane expres-
sion of memory-related receptors (NMDAR, EphB2 and 
InsR) that can not be attributed to spine loss but rather to a 
local synaptic alteration [226,259,263]. Using different  
preparations that are expected to yielded reasonable amount 
of low molecular weight oligomers, a major loss of postsyn-
aptic density protein, PSD95 [180,264], and synaptic recep-
tors, NMDA-R and AMPA-R [180,265-267], was also de-
scribed. Continued exposure to ADDLs resulted in abnormal 
spine morphology [226], with a temporary induction of long 
thin spines reminiscent of the morphology found in mental 
retardation, deafferentation, and prionoses [173]. We have 
observed a transient increase in synaptic boutons size at time 
when some dendritic spines were elongated [114,249] which 
would suggest that ADDLs might also be involved in reac-
tive synaptogenesis compatible with the concept that early 
stage synapse degeneration in AD includes adaptative en-
largement of presynaptic terminals [165,268]. Synaptic bind-
ing of ADDLs is associated to alterations of the F-actin cy-
toskeleton and the microtubule network as respectively dem-
onstrated by the redistribution and decrease of drebrin pro-
tein [226] and hyperphosphorylation of tau [269]. The likeli-
hood of a link between  and NFT was reinforced by the 
demonstration of tau hyperphosphorylation nearby   in 
vitro and in vivo. Abnormalities in Tau phosphorylation and 
cleavage can be induced by aggregated  [270-272]. Neu-
rofibrillary pathology and cortical neurodegeneration coexist 
in Tg models expressing both mutant human tau and APP as 
well as in  injected tau mutant (P301L) animals [39,273, 
274]. However, NFT pathology is a major characteristic of 
neurodegenerative diseases that can take place in the absence 
of -amyloidosis (e.g. frontal temporal dementia and parkin-
sonism-linked to chromosome 17, Pick’s disease, progres-
sive supranuclear palsy, corticobasal degeneration and argy-
rophilic grain disease [275,276]. PS1 mutants presenting tau 
pathology of the FTD-type but no  pathology might indi-
cate that even so  can trigger downstream phosphoryla-
tion of tau; tau can not initiate -deposition. 
Ultimately, ADDLs caused a significant decrease in 
spine density observed without neuronal degeneration as 
represented in Fig. (2) [114,115,226]. Other research groups 
have reported similar observations. ADDLs can change syn-
aptic connections by reducing the number of synaptic spines 
and altering both their morphology and motility [277]. Addi-
tionally, dendritic spine loss and transient spine elongation 
were surveyed in the presence of naturally secreted oli-
gomers [244,278] and  preparations containing oligomers 
[182,266]. 
In summary, the synaptic attack by ADDLs seems to of-
fer a mechanistic link between various facets of early events 
in AD pathogenesis such as synapse loss [226], AD-type tau 
hyperphosphorylation [269], ROS formation [279], brain 
insulino-resistance [263] and selective neurodegeneration 
providing strong evidence for their involvement in memory 
impairment and ultimately dementia [114,115]. These find-
ings suggested that ADDLs might act as gain-of-function 
ligands causing aberrations in signaling cascades related to 
LTP/LTD and memory but the cellular and molecular events 
underlying the toxic effects of A oligomers is not entirely 
known. Only recently have the effects of A oligomers on 
LTP and LTD been characterized, revealing the involvement 
of certain receptors and signaling pathways that will be dis-
cussed in the next section.  
The neurological properties of oligomers and their pres-
ence in AD brain coupled to the reversibility of memory loss 
in mouse models provide strong support for the hypothesis 
that AD is an oligomer-induced synaptic failure [19,101, 
103]. This hypothesis was significantly strengthened by the 
above demonstration that synapses are indeed the actual 
point of attack by oligomers where the oligomers produce 
their toxic effects by landing on particular post-synaptic re-
ceptors. 
 
 
 
 
 
 
 
 
 
 
Fig. (2). ADDL binding to dendritic spines causes time-dependent 
changes in dendritic spine morphology and density as illustrated 
here by drebrin immunoreactivity, a dendritic spine marker. Com-
puter-derived profile outlines were generated from a z-stack recon-
struction of single dendritic branche imaged from a confocal scan-
ning of drebrin-immunolabeled neurons. The treatment conditions 
represented here were in the following order ADDL 500nM for 
5min, ADDL 500nM for 6hrs, ADDL 500nM for 24hrs and Vehicle 
for 24hrs. The same threshold setting was applied under the treat-
ment conditions and show that both the dendritic spine density was 
decreased after ADDL treatment and that some spines are abnor-
mally long after a prolonged ADDL treatment.  
Synaptic binding of soluble  could result from a “fatal 
attraction” of these species with metal ions (e.g. zinc and 
copper) that are highly concentrated at synapses triggering a 
toxic cascade [280,281]. Alternatively, it has also been pro-
posed that globular and/or protofibrillar species could get 
inserted or bind to the lipid membrane bilayer instead of 
binding to membrane receptors. They would then create a 
pore that would confer an ion channel and induce down-
stream pathophysiological cellular responses resulting 
mainly from an interference with cellular ionic homeostasis 
[214,282,283].  
Even though the soluble oligomeric species seem to be 
occupying a vanguard position, the relative impact of the 
plaque-deposited  is still a focus of present research. We 
will conclude this section by saying that rather than asserting 
that only small soluble oligomers and not large insoluble 
deposits of  represent the sole neurotoxic entity, a con-
stant dynamic swap between the various forms should be 
pictured. In view of the severe abnormalities in synapses and 
neuronal processes associated to fibrillar deposits of , 
plaques and their surroundings might serve as reserve of 
soluble oligomeric  that are not yet detectable at the neu-
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propriate to attribute neuronal and synaptic dysfunctional 
activities to the soluble oligomeric species in the earliest 
stage of the AD process.  
SYNAPTOTOXIC MECHANISMS TRIGGERED BY 
SOLUBLE  OLIGOMERS OR ADDLs 
As synaptic dysfunction appears to be one of the main 
pathophysiological theories of AD [19,257,285], it is impor-
tant to find an etiological explanation for the alteration in 
synaptic signaling. In its initial appearance, the revised amy-
loid cascade claimed that synaptic dysfunction is one of the 
first presentations of AD pathology that is induced by  
toxicity but did not described the molecular pathway(s) by 
which  attains its hypothetical synaptotoxic function [19]. 
Synaptic dysfunction in human and AD-Tg manifested 
themselves as deficits in neurotransmission and synaptic 
scaling [156,267], decreased synaptic density and deficits in 
synaptic plasticity [19,103,118,226]. Nevertheless, the de-
scribed interference of ADDLs with synaptic transmission 
efficacy point to possible alterations in the intricate coordi-
nation of multiple specialized proteins involved either in 
synaptic vesicle trafficking or pre- and/or post-synaptic 
structure and plasticity [286]. Mechanisms underlying the 
effects of soluble  on synapse dysfunction are not exactly 
known, although  disturbs a plethora of cellular processes 
that ultimately could lead to decreased cell viability. It is 
likely that several degenerative pathways act simultaneously.  
Comparison of gene expression in 3 different AD-Tg at 2 
different ages reported a pretty good match between up- and 
down-regulated genes in these mice and what was previously 
reported in human AD brains [139,141]. The main category 
of genes that are commonly upregulated in these mice and 
AD, comprised genes involved in calcium and kinase signal-
ing, growth factor and their receptor signaling, gene tran-
scription, oxidative stress protection, lipid and cholesterol 
metabolism, cellular adhesion, lysosomal activation and in-
flammation. While, the key genes that are downregulated 
belong to the groups of genes involved in kinase and phos-
phatases signaling, trophic and growth factors, ion channels, 
protein metabolism, mitochondrial enzymes, transcription 
and translation and synaptic and vesicle transport. Down -
regulation of particularly interesting genes, in view of the 
synaptic failure hypothesis, affected those encoding for the 
glutamate NMDA and AMPA receptors, potassium and cal-
cium channels and CamKII. Downregulation taking place 
later concerned genes of the Ras GTPase activation protein, 
the Ephrin receptors, GBA-A receptor, the synaptic vesicle 
transport proteins, the insulin-like growth factor binding pro-
tein and BDNF (for more details, see [141]). The changes in 
gene expression were exacerbated when large amounts of  
deposits were present but were already observable at times of 
soluble   production. Similarly, five times more genes 
were modified in established AD compared to early AD 
[139]. These findings are compatible with some of the patho-
logical processes previously reported including abnormal 
synaptic plasticity and structure. 
Here we will focus on cellular processes that can be at-
tributed to specific  oligomeric forms and can be placed 
in the pathogenic cascade. Some mechanisms have recently 
emerged as depicted on Fig. (3). Further details can be found 
in the following reviews [156,235,287,288]. 
Oxidative Stress 
Oxidative stress is one of the strongest explanations for 
neuronal dysfunction related to alteration of neuronal signal-
ing mechanisms and has been extensively described else-
where [65,289,290]. Inhibition of LTP by soluble  might 
result from the activation of stress kinases and oxidative 
stress mediators through NMDARs, mGluR5, TNF death 
receptor or v integrin [235,289]. Different  oligomeric 
forms induced oxidative stress [279]. In addition, some syn-
aptic protein genes present a highlighted susceptibility to 
oxidative stress damage and can be downregulated [291]. 
Calcium Dyshomeostasis 
Increase calcium influx is highly related to the presence 
of various forms of  and has been extensively described 
(see reviews [292,293]). More precisely, A peptides depos-
ited in the dendritic arbor caused an increase in dendritic 
Ca
2+ [294] and to local dendritic spines [278]. 
Involvement of the Glutamate Receptors 
The understanding of the functions exerted by the thou-
sand proteins that constitute the synapse has just started with 
the definition of how some of them interact with each other 
in that unique neuronal compartment. Only a part of them 
have been well characterized making the comprehension of 
the exact molecular mechanism used by synaptically bound 
ADDLs even more difficult. One of the best functionally 
studied constituent of the synaptic machinery complex is the 
so called NMDA-R complex/MAGUK associated signaling 
complex (NRC/MASC) that contains ~185 proteins [295] 
with various possible functional interactions that are the cor-
nerstone of synaptic plasticity. In such a refined system, it is 
comprehensible that any displacement or alteration (e.g. due 
to posttranslational changes or modified protein structure) of 
few of the constituents would have major detrimental effect 
to synaptic functions.  
Several studies have described altered glutamate recep-
tors expression in the hippocampus of AD. Any alteration in 
expression and distribution would have severe consequences 
on synapse function and neuronal homeostasis because of 
their role in excitatory synaptic transmission.  
Expression of NMDAR subunits 1 and 2B, analyzed in 
the hippocampus throughout the progression of AD, was 
significantly decreased compared to control brains [296, 
297]. In our hippocampal culture model, ADDLs triggered a 
decrease of both NR2B and NR1 at the plasma membrane 
level [226,259]. Soluble  oligomer-induced LTP impair-
ment necessitates the activation of group I metabotropic glu-
tamate receptor activation [234]. 
Even so we found association between ADDLs and 
NMDAR [226], we do not know if it is through a direct in-
teraction. However prevention of ADDL-triggered dendritic 
spine loss by memantine, an uncompetitive NMDAR open-
channel antagonist [226] and interference with the NMDAR 
signaling pathway in the presence of the naturally secreted 
oligomers [278] strongly suggests the contribution of 
NMDAR in soluble  synaptotoxicity. Memantine is used 
to treat the symptoms of AD and works by decreasing 496    Current Genomics, 2007, Vol. 8, No. 8  Pascale Nathalie Lacor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Summarized neurotoxic mechanisms of synaptically bound ADDLs. 
Proposed mechanistic pathway for synaptically-bound ADDLs implicated in the induction of aberrations in dendritic spine composition and 
morphology and how this mechanism is related to synaptic dysfunction and connectivity loss in AD.  generated by cleavage of APP can 
accumulate and adopt oligomeric conformations of the ADDL-type that will bind to a postsynaptic membrane receptor (protein X) not yet 
identified but putatively located in the NMDA-R complex triggering Ca2+ influx followed by various changes in kinases/phosphatases activ-
ity that lead to: 1) reorganization of memory-essential receptors (NMDA-R, AMPA-R, EphB and InsR) from the cell surface most probably 
due to faulty receptor endocytosis. Various mechanisms have been proposed: one of them implicated Arc overexpression in the withdrawal of 
AMPA-R, while another suggested that NMDA-R endocytosis results from ADDL-induced activation of the a7nAchR and participation of 
signaling molecules such as STEP and Fyn. Alterations in dynamin 2 and endophilin, an enzyme involved in endocytic machinery controlling 
receptor turnover, has also been proposed. 2) deregulation of actin cytoskeletal dynamics which might result from the activation of Arc. At 
this level, rearrangement inside the actin-binding protein network, which is partially composed of Arc, Drebrin, Cofilin and Spinophilin, takes 
place disrupting the “spine morphology motor” and therefore proper synaptic plasticity. PAK and RhoGTPases activities are believed to play 
a major role in the actin cytoskeleton dynamics, its reduced activity leading to loss of drebrin and activation of cofilin, an actin-
depolymerizing molecule. 3) Modifications of the microtubule network examplified by the hyperphosphorylation of tau and the alterations in 
tubulin and MAP2 (not represented here). 4) Possible interference with expression of survival and “killer” genes through the CREB pathway. 
For clarity purpose, other possible factors (e.g. oxidative stress, mitochondrial dysfunction, presynaptic neurotransmitter release) that might 
be implicated in synaptic receptor expression and spine morphology have been omitted.  Advances on the Understanding of the Origins of Synaptic Pathology in AD  Current Genomics, 2007, Vol. 8, No. 8    497 
 
 “hyperactivation” of NMDAR [298] therefore provid-
ing memory benefits possibly by reducing ADDL-induced 
calcium influx and related downstream signaling cascade as 
well as Arc overexpression. Excessive activation of NMDAR 
was reported to produce spine loss [299] which would agree 
with the idea that soluble  by “overexciting” the NMDAR 
set off spine loss described above. 
It is thought that the release and uptake of the neuro-
transmitter glutamate is dysfunctional in AD, leading to an 
elevated neuronal influx of calcium triggering downstream 
neurotoxic pathways, a neurodegenerative cascade that can 
partially be alleviated by memantine.  
In an elegant study, it was proposed that activation by  
of the 7nAchR and downstream tyrosine phosphatase STEP 
is required to elicit the internalization of NMDAR in cul-
tured hippocampal neurons [265]. The activation of STEP is 
responsible for the dephosphorylation of NR2B and the inhi-
bition of Fyn, another tyrosine kinase which can phosphory-
late NR2B. These events drive the decrease of NMDAR sur-
face receptors both by interfering with endocytic pathway 
and blockage of the exocytosis of new NMDAR at the sur-
face [300].  
A species can selectively bind with picomolar affinity to 
7 nAChR [301], directly modulate nAChRs [302], block 
the 7 nAChR mediated responses [303] and activate mito-
gen-activated protein kinase (MAPK) cascade via  7 
nAChRs [304]. In addition, nicotine and nicotinic agonists 
have effects against A toxicity [305]. However, blockage of 
a7nAchR by -bungarotoxin was not complete suggesting 
the possible involvement of additional receptor mechanisms 
in  synaptotoxicity.  
AMPARs  
42 attenuates AMPAR function [306], reduces ampli-
tude and frequency of AMPAR mediated excitatory postsyn-
aptic currents in hippocampal CA1 neurons and reduces the 
opening probability and open time of the channel [266,267]. 
Both AMPAR and NMDAR currents were downregulated in 
hippocampal slices incubated with a virus containing hAPP 
[59]. AMPAR subunit GluR2 is significantly decreased in 
AD prior to NFT formation [307]. GluR2 is critical for keep-
ing AMPAR impermeable to calcium ions; therefore its de-
crease considerably affects synaptic function and neuronal 
viability. Data on GluR1 levels in AD brains did not show 
correlation with disease severity [308]. 
Furthermore, AMPAR internalization occurs downstream 
of group 1 mGluR activation [309], and could potentially 
explain the complete decay of short-term potentiated re-
sponses observed after A-oligomer exposure in LTP ex-
periments [116,118]. The endocytosis of AMPAR under  
exposure uses signaling pathways of LTP such as p38MAPK 
and calcineurin/PP2B [266]. Activity of PP2B seems also 
required for NMDAR withdrawal [265].  
mGluRs  
Elongation of spines is typically associated with a mod-
erate increase in intracellular calcium levels resulting from 
intracellular store release triggered by activation of me-
tabotropic receptors such as group 1 mGluRs [310]. Activa-
tion of group 1 mGluRs is critical for soluble A induced 
LTP impairment, and provides a reasonable link between the 
observed spine elongation and ADDL exposure. 
Activation of mGluR have been shown to rapidly in-
crease the aggregation of polyribosomes and to increase 
spine size [310]. Involvement of the mGluRs in the -
mediated reduction of glutamatergic transmission has been 
postulated, while activation of this synaptic transmission 
type is increased through activation of presynaptic 42 
nAchRs [311].  
NMDAR-Associated EphB Receptor 
EphB receptor tyrosine kinases represent another synap-
tic receptor essential for hippocampal synaptic plasticity and 
proper postsynaptic specialization [312]. Its activation in-
duces an extracelluar interaction with NMDAR1 [313] pro-
moting enhanced NMDAR Ca2+ influx and clustering of 
NMDAR with CaMKII recruited to the PSD for proper 
synaptic transmission [313]. Interestingly, mice expressing a 
truncated form of EphB2 without the tyrosine kinase site 
presented lower spine density and longer spine length [314].  
EphB2 activation promotes the synaptic recruitment of 
the Rho-GEF kalirin and the activation of Rac1 and its effec-
tor PAK, a downstream effector of the Rho/Rac family of 
small GTPases [315]. The activation of PAK regulates sig-
naling cascades that cause actin rearrangements and spine 
morphogenesis [316] and its inhibition has been associated 
with severe mental retardation and memory deficits [317]. 
Neuronal exposure to A oligomers causes a direct loss in 
neuronal PAK signaling suggesting that the loss of surface 
NR1 by short-term ADDL treatment may then instigate the 
reduction of EphB2 surface density. Loss of these receptors 
at the synapse is believed to induce defects in the PAK sig-
naling pathway, presumably through changes in synaptic 
recruitment of kalirin and Rac1. Changes in this pathway 
have been proposed to be responsible for the drebrin loss and 
aberrant spine structure observed with ADDL treatment 
[317].  
One might speculate that this series of events is responsi-
ble for the loss of connectivity responsible for memory defi-
cits in the AD brain, as NMDAR, AMPAR and EphB recep-
tors are important for plasticity and spine structure.  
Disorganization of the PSDs  
Concomitantly to the reported changes in memory-
essential receptors (see above),  has been shown to insti-
gate the degradation of PSD95, a “multi-partners” molecule 
binding scaffolding and cytoskeletal proteins as well as ad-
hesion and signaling molecules and glutamate receptors 
[248]. The PSD95 complex represents a network of molecu-
lar components providing compartmentalization and speci-
ficity for both temporal and spatial organization in signaling 
pathways [318]. PSD95 regulates AMPAR and NMDAR 
receptor trafficking [319,320] which would explain why its 
soluble A-induced degradation is concomitant to lower 
surface expression of these glutamate receptors [264]. 
Corruption of the F-Actin Cytoskeleton Complex (Arc, 
Drebrin and Cofilin) and Involvement of RhoGTPases 
Signaling Cascade (Rac/Rho/cdc42, PAK, LIMK) 
Morphological plasticity of spines depends on an intact 
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of actin-containing microfilaments (review in [321] and ref-
erence therein) and many cytoskeletal associated proteins 
that cross-link actin filaments to the plasma membrane and 
to the PSD itself [322]. The level of F-actin in the spine is 
determined by an equilibrium between polymerized and de-
polymerized actin (Fig. 3), a phenomenon highly controlled 
by actin regulatory and binding proteins (e.g. ADF/cofilin, 
profilin) that are synchronized by the PSD-network [323]. 
Dynamic changes in F-actin are linked to postsynaptic 
NMDAR [324] and determine the capacity of the spines to 
go through morphological changes [325]. Key pathways 
pairing actin remodeling and NMDAR have been recently 
reviewed [312]. As mentioned above, -induced changes in 
NMDAR and EphB2 receptors expression at the synaptic 
surface, without changing their total amount, may cause 
downstream signaling defects in the PAK pathway. Some of 
these signaling modifications may elicit actin rearrange-
ments, therefore antagonizing spine motility and impairing 
synaptic plasticity leading to the unconventional presentation 
of dendritic spine structure and density observed with pro-
longed ADDL treatment. 
A main pathway undergoes regulation of RhoA and Rac1 
(small RhoGTPases, [327]), key mediators of synaptic plas-
ticity [327]. Rac1 plays a main role in the regulation of F-
actin polymerization, implicating it in the maintenance
 and 
reorganization of dendritic structures, both at the level of 
their stability and motility [326,328]. Rac1 activation pro-
motes spine formation filopodia-like (elongated spines with-
out growth of spine heads) to the detriment of normal spines 
while its inhibition is linked to decreased spine density. To 
the contrary, RhoA activation leads to a reduction of spine 
length and density while its inhibition results in motility of 
new spines [326,329,330]. Considering the spine morphol-
ogy and density changes observed in soluble A oligomer-
treated neurons, it seems that both paths could occur simul-
taneously throughout the dendrites and maybe differentially 
among dendritic spines. This would, at least for a determined 
time, lead to the mixture of spine withdrawal and spine ex-
tension we have observed after ADDL incubation of hippo-
campal neurons [226]. Activation of Rac1 has been shown to 
occur after exogenous application of A [104,331] and is 
observed in AD and AD-Tg brains [332]. PAK, a Rac1 ef-
fector, and ADF/cofilin, a downstream actin depolymerizing 
protein were independently thought to be implicated in AD 
[317]. Downregulation of cofilin occurs after its phosphory-
lation by PAK/LIMK pathway [333,334], therefore reduc-
tion of PAK and LIMK like what is observed in AD and AD-
Tg would upregulate cofilin and disorganize actin complex. 
In fact, PAK seems to play an essential role in the synapto-
toxic cascade of soluble A oligomers because its overex-
pression prevents A oligomer-induced drebrin loss while its 
inhibition causes drebrin loss and definite memory deficits 
[317]. Rac1 was also reported to be essential in the A-
induced signaling cascade that leads to the generation
  of 
ROS in astroglioma cells [335]. Rho is in charge of the regu-
lation of clustering between F-actin and actin-binding pro-
teins such as spinophilin and neurabin. It is therefore ex-
pected in the case of  synaptotoxcity that alterations in 
synaptic protein stoechiometry between F-actin, drebrin, 
Arc, spinophilin and cofilin would occur.  
Interestingly, we have reported that soluble  oligomers 
targeted synapses in cultured rat hippocampal neurons where 
they triggered sustained overexpression of the immediate-
early gene Arc [114,115,122]. Arc protein has an essential 
role in long term memory formation and synaptic plasticity 
[223,336] and is known to regulate both the state of F-actin 
and microtubule network by interacting with MAP2. We 
have predicted that ADDLs by increasing Arc expression 
would interfere with glutamate receptor expression at the 
surface and cause aberrations in spine shape [122]. This pre-
diction has largely been confirmed [226,259,265,266]. 
Moreover, Arc has been granted a function in AMPAR traf-
ficking by promoting receptor endocytosis after interaction 
with two proteins of the endocytic vesicle membrane (dy-
namin and endophilin) [337]. Compatible with the deleteri-
ous effect of  at synapses, Arc overexpression downregu-
lated AMPAR surface expression [338], induced a reduction 
of AMPAR-mediated synaptic transmission [339] and 
blocked the homeostatic increase in AMPAR function [340]. 
Even so NMDAR downregulation from the cell surface pre-
dicts a decrease in Arc mRNA translation at the synapse, Arc 
expression might be deregulated and elevated when AMPAR 
are withdrawn from the membrane because they normally 
serve as a negative regulator of Arc transcription [341]. We 
do not know yet if Arc could disrupt cycling of other synap-
tic receptors required for synaptic plasticity. 
Spinophilin bundles actin, but also facilitates synaptic 
transmission by recruiting protein phosphatase to the syn-
apse to modulate glutamate receptor activity [342]. The im-
pact of the unbalanced regulation inside the postsynaptic 
actin-regulatory machinery (loss of drebrin associated to 
increase dephosphorylated cofilin) and its role in synaptic 
dysfunction characteristics of AD and DS was nicely re-
viewed elsewhere [184]. This drebrin/actin-regulatory pro-
teins/F-actin complex is highly regulated by NMDAR activ-
ity [325].  
Tyrosine Kinases and MAP Kinases 
Evidence also suggested that A oligomers bind to neu-
ronal membrane proteins [119,121] resulting in activation of 
kinase signal transduction pathways [101,343,234].  was 
shown to regulate the function of PKA, calcineurin and 
CREB [344,345].  
1-42, under fibrillar or soluble conformation, can in-
duce a sustained activation of ERK1/2 signaling pathway 
which can then lead to hyperphosphorylation of Tau [271, 
346,347]. In the case of soluble  oligomers (Os), 
caspase-3 activation following the stimulation of the ERK1/2 
signaling pathway leads to proteolytic cleavage of tau [272] 
without synapse degeneration. This suggests that oligomers 
can induce microtubule damage. 
Other pathways involving PKC [348], JNK, cdk5 and 
p38 MAPK [234] have been proposed for -mediated tox-
icity implicating possibly different signaling pathway activa-
tion that might very well be due to the use of different con-
formational  species or particularities in the experimental 
protocols used. 
Other studies implicated Fyn, a src-family tyrosine 
kinase, in the toxicity of soluble A oligomers. Initial dem- 
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onstrations elegantly pointed out to Fyn as an essential ele-
ment in synaptotoxicity as knock-out of Fyn in cells and 
hAPP-Tg mice protects against A toxicity [101,343] while 
Fyn overexpression exacerbated the loss of synaptic markers 
and subsequent memory dysfunction [343,349].  
Insulin Pathway 
Soluble  oligomers have very recently been shown to 
interfere with insulin receptors present in the brain providing 
a basis for CNS insulin resistance in AD [115,263]. Mecha-
nisms of ADDL-induced InsR withdrawal from the cell sur-
face have not been described yet but it is becoming clear that 
soluble  greatly reduces the responsiveness of the neurons 
to insulin. Concomitantly, a report showed that naturally 
secreted oligomers interfere with ERK/MAPK, CaMKII and 
PI3K/Akt, effects that are supposedly resulting from the 
binding of  oligomers to the InsR [350], if so it is specu-
lated that insulin would provide protection against some A-
induced synaptotoxic effects. Competition between A and 
insulin for InsR binding site results in a decrease in InsR-
mediated signaling [263,350-352]. Indeed, insulin can pro-
tect against A cytotoxicity in hippocampal cell cultures 
[353] and can regulate the endocytosis of AMPAR [354]. 
Other Events Relevant to Synaptotoxicity  
Alterations in the synaptic vesicle trafficking were re-
ported in neurons exposed to  species [355]. Briefly, A 
triggers an increase in intracellular calcium most probably 
through the activation of voltage-gated calcium channels. 
This activates subsequently the calpain enzyme which has 
dynamin-1 for substrate. Dynamin-1 is a GTPase protein 
which participates in the exo/endocytosis mechanisms by 
helping the recycling of synaptic vesicles from the plasma 
membrane after neurotransmitter release [356]. A hence 
accentuates neurotransmitter release. 
At the same time,  can also induce proteasome dys-
function by inhibiting the ubiquitin C-terminal hydrolase 
[357] which could in turn lead for example to accumulation 
of tau [358] and improper turnover of PSD protein [264] thus 
it is legitimate to hypothesized that the various events de-
scribed above will ultimately lead to abnormal PSD compo-
sition.  
PERSPECTIVES – CONCLUSIONS 
While the cellular and molecular events underlying the 
toxic effects of A oligomers are not entirely known, it is 
evident that soluble  oligomers have synaptotoxic effects 
and contribute to the increasing body of knowledge regard-
ing the molecular basis for memory loss in AD. We pro-
posed that the selective targeting of ADDLs to the post-
synaptic sites creates an inappropriate organization of the 
cytoskeletal and scaffolding PSD network. Association and 
activation of signaling molecules at the PSD are disrupted 
which in turn alter the modulation of actin-based spine mor-
phology and receptor distribution contributing to early cog-
nitive deficits of AD. Synaptic disruption by ADDLs might 
even derive from modulations of multiple signaling path-
ways and cytoskeletal reorganization. Gradually more under-
standing of the molecular biology of early AD will provide 
new therapeutic targets. 
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